Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol 2008 Nov 01;26(31):5134-6; author reply 5136-7
Date
10/08/2008Pubmed ID
18838697DOI
10.1200/JCO.2008.19.1841Scopus ID
2-s2.0-55549116005 (requires institutional sign-in at Scopus site) 60 CitationsAuthor List
Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D'Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, Ponzoni MAuthor
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Female
Follow-Up Studies
Humans
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Rituximab
Survival Analysis
Time Factors
Treatment Outcome
